Association Between Neutrophil-Lymphocyte Ratio and Oncotype Dx Recurrence Score in Early-Stage Hormonal Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer

被引:1
|
作者
Alshamsan, Bader [1 ,2 ]
Alshibany, Aisha [1 ]
Elshenawy, Mahmoud A. [1 ,3 ]
Badran, Ahmed [1 ,4 ]
Elhassan, Tusneem [1 ]
Ajarim, Dahish [1 ]
Alsayed, Adher [1 ]
Suleman, Kausar [1 ]
Al-Tweigeri, Taher [1 ]
机构
[1] King Faisal Specialist Hosp & Res Ctr, Ctr Oncol, Med Oncol, Riyadh, Saudi Arabia
[2] Qassim Univ, Dept Med, Coll Med, Qasim, Saudi Arabia
[3] Menoufia Univ, Clin Oncol, Fac Med, Shibin Al Kawm, Egypt
[4] Ain Shams Univ Hosp, Dept Clin Oncol, Cairo, Egypt
来源
关键词
neutrophil-to-lymphocyte ratio; Oncotype Dx recurrence score; early-stage breast cancer; hormonal receptor-positive; human epidermal growth factor receptor 2-negative; node-negative breast cancer; GENE-EXPRESSION; TUMOR-MARKER; CHEMOTHERAPY; SURVIVAL; BENEFIT; RISK; PREDICTION; PROGNOSIS; SUBTYPE; WOMEN;
D O I
10.2147/CMAR.S343549
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The correlation between the preoperative neutrophil-to-lymphocyte ratio (NLR) and Oncotype DX (R) (ODX) recurrence score (RS) has not yet been established. We aimed to investigate the association between NLR and ODX RS in patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) early-stage breast cancer (BC). Patients and Methods: This retrospective study included consecutive patients with HR +/HER2-, node-negative primary BC who underwent surgical tumor resection from 2011 to 2019. Receiver operating characteristic curve analysis was used to obtain an optimal NLR cutoff value. Logistic regression analyses were used to estimate associations between various parameters and ODX RS. Furthermore, the factors significantly associated with the ODX RS in multivariable analysis were incorporated in a separate model and estimated using logistic regression. Results: A total of 160 patients were enrolled. The optimal preoperative NLR cutoff was 2.15. Multivariable analysis revealed that NLR and tumor grade (G1/G2 vs G3) were independent predictive factors of high RS cutoff (>= 26). Moreover, including the two variables yielded a stronger association; patients with low NLR and low-grade tumors were unlikely to have high RS (>= 26; odds ratio [OR] = 0.03, 95% confidence interval [CI]: 0.006-0.154; p < 0.001). Conversely, the presence of any of the following factors made patients unlikely to have low RS (<16; OR = 0.34, 95% CI: 0.16-0.73; p = 0.006): high NLR, high grade, or high Ki-67 levels (>20). Conclusion: NLR is a promising independent predictor of RS. Furthermore, in addition to tumor grade and Ki-67 level, they together are also a potential indicator of high and low RS. However, further studies are required to validate this hypothesis.
引用
收藏
页码:9411 / 9420
页数:10
相关论文
共 50 条
  • [41] Ki-67 Proliferative Index in Estrogen Receptor-Positive/HER2-Neu Negative Early Breast Cancer Predicts Oncotype DX Recurrence Score
    Kelly, C.
    Saad, R. S.
    Nofech-Mozes, S.
    Kahn, H.
    Zubovits, J.
    Wong, J.
    Hanna, W. M.
    [J]. MODERN PATHOLOGY, 2010, 23 : 55A - 55A
  • [42] Comparison of Oncotype Dx (ODx) 21-gene recurrence score (RS) in African American (AA) and Caucasian (C) patients with hormone receptor-positive (HR+), HER2-negative (HER2-), lymph node-negative (LNN) breast cancer (BC)
    Kabaker, K. B.
    Canar, J.
    Rao, R. D.
    Cobleigh, M. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [43] The financial burden of using Oncotype Dx for patients with lymph node-negative and estrogen receptor-positive breast cancer in Australia
    Sakata, Shinichiro
    Cronk, Michelle
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (01) : 94 - 95
  • [44] Safely Omitting Sentinel Lymph Node Biopsy in Women 70 Years Old with Early Stage, Clinically Node-Negative, Estrogen Receptor-Positive, HER2-negative Breast Cancer
    Seo, Dianne
    Sizer, Lina
    Roudakova, Kseniya
    Kjelstrom, Stephanie
    Carruthers, Catherine C.
    Carter, William B.
    Lamb, Elena
    Frazier, Thomas G.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (SUPPL 2) : 419 - 419
  • [45] Clinical outcomes and Oncotype DX Breast Recurrence Score (R) in early-stage BRCA-associated hormone receptor-positive breast cancer
    Layman, Rachel M.
    Lin, Heather
    Barrera, Angelica M. Gutierrez
    Karuturi, Meghan S.
    Yam, Clinton
    Arun, Banu K.
    [J]. CANCER MEDICINE, 2022, 11 (06): : 1474 - 1483
  • [46] Treatment of Lymph Node-Negative, Early-Stage HER2-Positive Breast Cancer Reply
    O'Sullivan, Ciara C.
    Holmes, Eileen
    Campbell, Christine
    Bradbury, Ian
    Zujewski, Jo Anne
    Gelber, Richard D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (06) : 640 - +
  • [47] What Is the Optimal Model to Estimate the Benefits of Chemotherapy in Patients With Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer?
    Ando, Kenju
    Shimomura, Akihiko
    Yoshimura, Kenichi
    Kawamura, Yukino
    Shimizu, Chikako
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (17) : 1946 - +
  • [48] Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial
    Albain, Kathy S.
    Gray, Robert J.
    Makower, Della F.
    Faghih, Amir
    Hayes, Daniel F.
    Geyer, Charles E., Jr.
    Dees, Elizabeth C.
    Goetz, Matthew P.
    Olson, John A., Jr.
    Lively, Tracy
    Badve, Sunil S.
    Saphner, Thomas J.
    Wagner, Lynne, I
    Whelan, Timothy J.
    Ellis, Matthew J.
    Wood, William C.
    Keane, Maccon M.
    Gomez, Henry L.
    Reddy, Pavan S.
    Goggins, Timothy F.
    Mayer, Ingrid A.
    Brufsky, Adam M.
    Toppmeyer, Deborah L.
    Kaklamani, Virginia G.
    Berenberg, Jeffrey L.
    Abrams, Jeffrey
    Sledge, George W., Jr.
    Sparano, Joseph A.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (04) : 390 - 399
  • [49] Comparison of the prognostic performance between OncoMasTR and OncotypeDX multigene signatures in hormone receptor-positive, HER2-negative, lymph node-negative breast cancer
    Kelly, Catherine Margaret
    Crown, John
    Russell, Niamh
    Barron, Stephen
    Lynch, Seodhna
    O'Grady, Anthony
    Sheehan, Katherine
    Fay, Joanna
    Amberger-Murphy, Verena
    Saha, Anurati
    Loughman, Tony
    Dynoodt, Peter
    Fender, Bozena
    Ruiz, Cesar Lopez
    Wang, Chan-Ju Angel
    O'Leary, Desmond
    O'Connor, Darran
    Gallagher, William M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [50] Can Features Evaluated in the Routine Pathologic Assessment of Lymph Node-Negative Estrogen Receptor-Positive Stage I or II Invasive Breast Cancer Be Used to Predict the Oncotype DX Recurrence Score?
    Auerbach, Jena
    Kim, Mimi
    Fineberg, Susan
    [J]. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2010, 134 (11) : 1697 - 1701